Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions

Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunitiesSAN ANTONIO, TX / / September 23, 2026 / Valion Bio, Inc. NASDAQ:VBIO ("Valion" or the "Company"), a clinical-stage biopharmaceutical c…